DDInter537 DDInter1435
Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Diclofenac {u} (Compound) resembles {v} (Compound) Clonidine
Diclofenac {u} (Compound) resembles {v} (Compound) Nepafenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromfenac
Diclofenac {u} (Compound) binds {v} (Gene) ALOX5
Diclofenac {u} (Compound) palliates {v} (Disease) systemic scleroderma
Diclofenac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Diclofenac {u} (Compound) downregulates {v} (Gene) PUF60
Diclofenac {u} (Compound) causes {v} (Side Effect) Corneal disorder
Diclofenac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Colestipol
Diclofenac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cholestyramine
Diclofenac (Compound) resembles Clonidine (Compound)
Diclofenac (Compound) resembles Nepafenac (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Diclofenac (Compound) binds ALOX5 (Gene)
Diclofenac (Compound) palliates systemic scleroderma (Disease)
Diclofenac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Diclofenac (Compound) downregulates PUF60 (Gene)
Diclofenac (Compound) causes Corneal disorder (Side Effect)
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Colestipol
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cholestyramine